In a pregnant woman with hyperthyroidism who develops an itchy rash from methimazole, should methimazole be stopped and propylthiouracil (PTU) continued, and how should the PTU dose be adjusted?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Switch to Propylthiouracil and Continue Treatment

In a pregnant woman with hyperthyroidism who develops an itchy rash from methimazole, you should immediately discontinue methimazole and switch to propylthiouracil (PTU), using a dose conversion ratio of approximately 10:1 (100-150 mg PTU for every 10 mg methimazole). 1

Rationale for Switching

The Endocrine Society guidelines explicitly state that "MMI may also be prescribed if PTU is not available or if a patient cannot tolerate or has an adverse response to PTU" 1. This recommendation works bidirectionally—when methimazole causes an adverse reaction like rash, PTU becomes the appropriate alternative regardless of trimester.

The FDA drug label for methimazole confirms that allergic reactions including rash are recognized adverse effects that may necessitate drug discontinuation 2. While desensitization protocols exist 3, 4, they are not appropriate during pregnancy when a safer alternative (PTU) is readily available.

Dose Conversion and Monitoring

Convert using the 10:1 ratio: If the patient was on methimazole 20 mg daily, switch to PTU 200-300 mg daily (divided into 2-3 doses, as PTU has a shorter half-life) 1.

Critical monitoring requirements:

  • Check thyroid function (TSH and free T4) 2 weeks after switching, then every 2-4 weeks 1
  • Monitor liver function every 3-4 weeks while on PTU, as hepatotoxicity is a serious risk 1, 5
  • Instruct the patient to immediately report fever, sore throat (agranulocytosis), or symptoms of liver dysfunction (anorexia, pruritus, right upper quadrant pain) 5

Treatment Goals

Maintain maternal free T4 at the upper limit of the non-pregnant reference range or total T4 at 1.5 times the upper limit of normal 1. This prevents both maternal complications and fetal hypothyroidism from overtreatment.

Important Caveats

PTU carries significant hepatotoxicity risk: The FDA has issued warnings about severe liver injury, including acute liver failure, particularly concerning in pregnancy 1, 5. However, this risk must be balanced against:

  • The teratogenic risk of methimazole (aplasia cutis, choanal/esophageal atresia, facial dysmorphism) 2, 6
  • The severe maternal and fetal complications of untreated hyperthyroidism (preeclampsia, heart failure, fetal death, intrauterine growth restriction) 1, 7

Do not attempt to switch back to methimazole during pregnancy after a documented allergic reaction. The standard recommendation to switch from PTU to methimazole after the first trimester 1 does not apply when the patient has demonstrated methimazole intolerance. Continue PTU throughout pregnancy with vigilant liver function monitoring.

Alternative if PTU Also Fails

If the patient develops severe adverse reactions to PTU (hepatotoxicity, agranulocytosis, or vasculitis), thyroidectomy in the second trimester becomes the definitive option 1. Surgery is indicated when:

  • Severe adverse reaction to antithyroid drugs occurs
  • Persistently high doses are required (>450 mg/day PTU)
  • The patient cannot achieve control despite maximum medical therapy

The second trimester is optimal timing to minimize both anesthetic risks and surgical complications 1.

References

Research

Desensitization to Methimazole.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2021

Research

Management of hyperthyroidism in pregnancy.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.